Xiamen Innovax Biotech CO., LTD. (Innovax) is a Chinese company that manufactures, markets, and develops

vaccines A vaccine is a biological preparation that provides active acquired immunity The adaptive immune system, also known as the acquired immune system, is a subsystem of the immune system that is composed of specialized, systemic cells and pro ...

. It is headquartered in Xiamen, Fujian, China.

Hepatitis E Vaccine (HEV 239)

In October 2012, Xiamen created the HEV 239 vaccine to treat

Hepatitis E Hepatitis E is inflammation of the liver caused by infection with the hepatitis E virus (HEV); it is a type of viral hepatitis. Hepatitis E has mainly a fecal-oral transmission route that is similar to hepatitis A, although the viruses are unrel ...

. The vaccine was approved by the Chinese Ministry of Science and Technology after it was tested during a controlled trial of 100,000+ people from the

Jiangsu Province Jiangsu (; ; pinyin: Jiāngsū, alternatively romanized as Kiangsu or Chiangsu) is an eastern coastal province of the People's Republic of China. It is one of the leading provinces in finance, education, technology, and tourism, with its ca ...

over a 12-month period. Of the 100,000 people treated, none were infected as compared to 15 that were infected from the controlled placebo group.

Other vaccines

The firm also has created a

cervical cancer Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Early on, typically no symptoms are seen. Later symptoms may include abnormal ...

vaccine that is currently under a phase III clinical trial, a

genital warts Genital warts are a sexually transmitted infection caused by certain types of human papillomavirus (HPV). They are generally pink in color and project out from the surface of the skin. Usually they cause few symptoms, but can occasionally be pai ...

vaccine that is under a phase II clinical trial, and a 9-valent

HPV Human papillomavirus infection (HPV infection) is caused by a DNA virus from the '' Papillomaviridae'' family. Many HPV infections cause no symptoms and 90% resolve spontaneously within two years. In some cases, an HPV infection persists and re ...

vaccine currently in the process of receiving clinical approval.

WHO position on HEV 239

The

World Health Organization (WHO) The World Health Organization (WHO) is a specialized agency of the United Nations responsible for international public health. The WHO Constitution states its main objective as "the attainment by all peoples of the highest possible level of ...

stated that the Phase I, II, and III clinical trials were effective and safe in healthy subjects, however the WHO has not made a recommendation regarding the HEV 239 Vaccine because of a lack of evidence in people 16 years of age or younger, and 65 years of age and older. China is currently the only country to approve the vaccine since Hepatitis E is rare in developed countries. There are further clinical trials planned before making the drug more generally available. to susceptible populations. The position of the WHO is that, however, national authorities may decide to use the vaccine based on the local epidemiology.

References

{{reflist Biotechnology companies of China Manufacturing companies based in Xiamen Vaccine producers